Michael Minogue appointed to Bioventus Board of Managers

326

Bioventus has announced the appointment of Michael Minogue, chief executive officer, president and chairman of Abiomed, to the company’s Board of Managers, replacing Evan Melrose.

“We are pleased to have Michael Minogue join our Board as we continue to grow Bioventus. His leadership at Abiomed, bringing life changing medical technologies through development and into the healthcare markets globally, will be invaluable to our mission to be a global leader in orthobiologics.” said Tony Bihl, chief executive officer of Bioventus.

“I look forward to working with the team at Bioventus and using my experience to help them advance more orthobiologic solutions that will benefit patients and health care professionals around the world,” says Minogue.

Since joining Abiomed in 2004, Minogue also represents the medical device industry by serving on the executive board of directors for AdvaMed, and as chairman of Medical Device Industry Consortium (MDIC).

Minogue formerly served on the board of LifeCell Corporation (LIFC) and is one of the co-founders and chairman of the MedTech and BioTech Veterans Program. He joined Abiomed after spending 11 years at General Electric Healthcare, where he also holds three patents.

Previously, Minogue also served as an infantry officer in the US Army, which included multiple distinctions including Airborne, RANGER, Desert Storm Veteran and Bronze Star. He received his Bachelor of Science degree in Engineering Management from the United States Military Academy at West Point and his MBA from the University of Chicago.

Leaving the Bioventus Board, is Evan Melrose, who has served as a board member since the inception of the company in 2012, and has decided to step down at this time.

“We thank Evan for all of his contributions to our success these past four years on our Board, including his tireless work on our compensation committee and his insights on biologics that has helped us shape the company,” says Bihl. “He will be greatly missed and we wish him well in all future endeavours.”